Search results

Order by most recent / most popular / relevance

Results: 1-10 of 554

Pharma in brief - Canada: Federal Court dismisses prohibition application for drospirenone YASMIN due to non-infringing process

Norton Rose Canada LLP
-
Canada
-
June 15 2013

Bayer Inc. and Bayer Pharma Aktiengesellschaft (“Bayer”) brought an application pursuant to section 6 of the Patented Medicines (Notice of

US Supreme Court releases Myriad, isolated DNA unpatentable what it means for Canada

Smart & Biggar/Fetherstonhaugh
-
Canada, USA
-
June 13 2013

The Supreme Court of the United States today issued its opinion in Association for Molecular Pathology et al. v. Myriad Genetics, Inc. et al., 569 U

After reconsideration, the Viagra patent is not void

Fasken Martineau DuMoulin LLP
-
Canada
-
June 11 2013

Close to seven months after rendering its decision in Teva Canada Ltd v Pfizer Canada Inc., 2012 SCC 60, the Supreme Court of Canada varied its

Intellectual property weekly abstracts bulletin

Borden Ladner Gervais LLP
-
Canada
-
June 10 2013

In November, the Supreme Court issued its decision in the sildenafil case, and, as part of its order, found the patent to be invalid. As this case was

The process is an essential element of a product-by-process claim

SIM. IP Practice
-
Canada
-
June 7 2013

Bayer attempted to broaden the scope of a product-by-process claim by arguing that the process recited in the claim was a non-essential feature and

Supreme Court varies VIAGRA ruling, confirms that patent is neither invalid nor void

Smart & Biggar/Fetherstonhaugh
-
Canada
-
June 6 2013

The Supreme Court of Canada has clarified its ruling in Teva Canada Ltd v Pfizer Canada Inc, 2012 SCC 60. The Court has confirmed that the patent in

Supreme Court amends earlier decision: Viagra patent not void

Bereskin & Parr LLP
-
Canada
-
June 6 2013

In Teva Canada Ltd v Pfizer Canada Inc, the Supreme Court of Canada (the "SCC") held Pfizer's Canadian Patent No. 2,163,446 (the '446 Patent) to be

U.S. patent seed case ruling aligns with Canadian patent protection laws

Blake Cassels & Graydon LLP
-
Canada, USA
-
June 3 2013

On May 13, 2013, the Supreme Court of the United States (SCOTUS) issued a unanimous decision in Bowman v. Monsanto Co. et al., holding that Vernon

PM(NOC) proceedings: Cobalt defeats Bayer’s Canadian patent on oral contraceptive YASMIN

McCarthy Tétrault LLP
-
Canada
-
May 31 2013

On May 29, 2013 Justice O'Reilly of the Federal Court dismissed Bayer PM Notice of Compliance (NOC) proceeding against Cobalt. The issue before the

Claim for section 8 damages allowed

Borden Ladner Gervais LLP
-
Canada
-
May 28 2013

In this case, Apotex claimed damages pursuant to s. 8 of the NOC Regulations, and Pfizer alleged that Apotex should not be entitled to damages, due to

next >

Search results

Pharma in brief - Canada: Federal Court dismisses prohibition application for drospirenone YASMIN due to non-infringing process

US Supreme Court releases Myriad, isolated DNA unpatentable what it means for Canada

After reconsideration, the Viagra patent is not void

Intellectual property weekly abstracts bulletin

The process is an essential element of a product-by-process claim

Supreme Court varies VIAGRA ruling, confirms that patent is neither invalid nor void

Supreme Court amends earlier decision: Viagra patent not void

U.S. patent seed case ruling aligns with Canadian patent protection laws

PM(NOC) proceedings: Cobalt defeats Bayer’s Canadian patent on oral contraceptive YASMIN

Claim for section 8 damages allowed

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea